company background image
4171

GeneReach BiotechnologyTPEX:4171 Stock Report

Market Cap

NT$4.6b

7D

-1.3%

1Y

-39.6%

Updated

24 Sep, 2021

Data

Company Financials
4171 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance5/6
Financial Health6/6
Dividends0/6

4171 Overview

GeneReach Biotechnology Corp. develops, manufactures, and markets products for applied nucleic acid detection technology primarily in Taiwan.

Price History & Performance

Summary of all time highs, changes and price drops for GeneReach Biotechnology
Historical stock prices
Current Share PriceNT$113.50
52 Week HighNT$104.00
52 Week LowNT$201.00
Beta0.55
1 Month Change4.13%
3 Month Change-12.36%
1 Year Change-39.63%
3 Year Change288.70%
5 Year Change336.54%
Change since IPO170.24%

Recent News & Updates

Apr 18
Does GeneReach Biotechnology (GTSM:4171) Have A Healthy Balance Sheet?

Does GeneReach Biotechnology (GTSM:4171) Have A Healthy Balance Sheet?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Shareholder Returns

4171TW Medical EquipmentTW Market
7D-1.3%-0.2%-1.0%
1Y-39.6%10.8%39.0%

Return vs Industry: 4171 underperformed the TW Medical Equipment industry which returned 10.8% over the past year.

Return vs Market: 4171 underperformed the TW Market which returned 39% over the past year.

Price Volatility

Is 4171's price volatile compared to industry and market?
4171 volatility
4171 Beta0.55
Industry Beta0.93
Market Beta1

Stable Share Price: 4171 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: 4171's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2004n/aGrace Changhttps://www.genereach.com

GeneReach Biotechnology Corp. develops, manufactures, and markets products for applied nucleic acid detection technology primarily in Taiwan. The company offers pathogen detection platforms, including equipment and reagents; and animal use medicines, biotechnology services, medical materials and equipment, and precision instruments. Its products are used in aquaculture, agriculture, food, companion animal, livestock, and human health industries.

GeneReach Biotechnology Fundamentals Summary

How do GeneReach Biotechnology's earnings and revenue compare to its market cap?
4171 fundamental statistics
Market CapNT$4.61b
Earnings (TTM)NT$362.07m
Revenue (TTM)NT$978.95m

12.7x

P/E Ratio

4.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
4171 income statement (TTM)
RevenueNT$978.95m
Cost of RevenueNT$240.44m
Gross ProfitNT$738.51m
ExpensesNT$376.45m
EarningsNT$362.07m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)8.92
Gross Margin75.44%
Net Profit Margin36.99%
Debt/Equity Ratio7.7%

How did 4171 perform over the long term?

See historical performance and comparison

Valuation

Is GeneReach Biotechnology undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 4171 (NT$113.5) is trading below our estimate of fair value (NT$633.21)

Significantly Below Fair Value: 4171 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 4171 is good value based on its PE Ratio (12.7x) compared to the TW Medical Equipment industry average (23.3x).

PE vs Market: 4171 is good value based on its PE Ratio (12.7x) compared to the TW market (16.4x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 4171's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 4171 is overvalued based on its PB Ratio (4.5x) compared to the TW Medical Equipment industry average (2x).


Future Growth

How is GeneReach Biotechnology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

14.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as GeneReach Biotechnology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has GeneReach Biotechnology performed over the past 5 years?

77.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 4171 has a high level of non-cash earnings.

Growing Profit Margin: 4171's current net profit margins (37%) are higher than last year (22.3%).


Past Earnings Growth Analysis

Earnings Trend: 4171 has become profitable over the past 5 years, growing earnings by 77.7% per year.

Accelerating Growth: 4171's earnings growth over the past year (175.9%) exceeds its 5-year average (77.7% per year).

Earnings vs Industry: 4171 earnings growth over the past year (175.9%) exceeded the Medical Equipment industry 9.5%.


Return on Equity

High ROE: 4171's Return on Equity (33.3%) is considered high.


Financial Health

How is GeneReach Biotechnology's financial position?


Financial Position Analysis

Short Term Liabilities: 4171's short term assets (NT$968.0M) exceed its short term liabilities (NT$247.3M).

Long Term Liabilities: 4171's short term assets (NT$968.0M) exceed its long term liabilities (NT$150.3M).


Debt to Equity History and Analysis

Debt Level: 4171's debt to equity ratio (7.7%) is considered satisfactory.

Reducing Debt: 4171's debt to equity ratio has reduced from 44.1% to 7.7% over the past 5 years.

Debt Coverage: 4171's debt is well covered by operating cash flow (208.8%).

Interest Coverage: 4171's interest payments on its debt are well covered by EBIT (106.6x coverage).


Balance Sheet


Dividend

What is GeneReach Biotechnology current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 4171's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 4171's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 4171's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 4171's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 4171's dividend in 3 years as they are not forecast to pay a notable one for the TW market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.7yrs

Average management tenure


CEO

Grace Chang

no data

Tenure

Ms. Grace Chang, Ph D., serves as Chief Executive Officer at GeneReach Biotechnology Corp. Ms. Chang holds Ph.D. in Nutritional Science and Toxicology from UC Berkeley in the year 1993 to 1998 and B.S. in...


Leadership Team

Experienced Management: 4171's management team is considered experienced (3.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

GeneReach Biotechnology Corp.'s employee growth, exchange listings and data sources


Key Information

  • Name: GeneReach Biotechnology Corp.
  • Ticker: 4171
  • Exchange: TPEX
  • Founded: 2004
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: NT$4.607b
  • Shares outstanding: 40.59m
  • Website: https://www.genereach.com

Location

  • GeneReach Biotechnology Corp.
  • Central Taiwan Science Park
  • No.19, Keyuan 2nd Road
  • Taichung
  • 407
  • Taiwan

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/24 08:33
End of Day Share Price2021/09/23 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.